Sunitinib is a cancer medicine. It helps stop the growth of certain types of cancer cells, like those in the stomach or kidney. It's taken as a pill, usually once a day. It's important to take it exactly as prescribed by your doctor.
Every report comes from a Lived member, sent anonymously.
Have you tried Sunitinib for Renal Cell Carcinoma?
Sunitinib, sold under the brand name Sutent and also available as a generic, is a targeted cancer medicine taken by mouth. It belongs to a group of drugs called kinase inhibitors and is approved for adults with three kinds of cancer. In kidney cancer (renal cell carcinoma, or RCC), it is approved for advanced disease, and after surgery to remove the kidney for adults at high risk of the cancer coming back. In gastrointestinal stromal tumor (GIST), a rare cancer that grows in the wall of the stomach or intestine, it is used when imatinib, another targeted pill, has stopped controlling the cancer or caused side effects a person could not tolerate. It also treats well-differentiated (slower-growing) pancreatic neuroendocrine tumors (pNET), which start in the hormone-producing cells of the pancreas, when they are growing and cannot be removed with surgery. Sunitinib's place in kidney cancer has changed since its approval. For a first treatment of advanced clear cell RCC, the most common type, combinations that include immunotherapy (medicines that help the immune system attack cancer) outperformed sunitinib in large trials and are now the usual standard. After kidney surgery, sunitinib delayed the cancer's return somewhat but did not help people live longer, so guidelines no longer recommend it routinely; it remains an option for people who cannot receive immunotherapy. Its safety and effectiveness in children have not been established.
Kinases are enzymes that work like switches inside cells, passing along signals that tell cells to grow, divide and build new tissue. Many cancers lean heavily on these signals. Sunitinib blocks several of these switches at once. Some of its targets are receptors for vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), signals tumors use to grow the new blood vessels that feed them. Blocking them is thought to be central to its effect in kidney cancer and pancreatic neuroendocrine tumors. PDGF receptors also sit on some cancer cells, so sunitinib blocks them there too, along with KIT, a growth-signal receptor whose overactivity drives most GISTs. The aim is to slow or shrink tumors and hold the cancer in check for as long as possible. In advanced cancer, sunitinib controls the disease rather than curing it, and over time many cancers stop responding.
Sunitinib comes as capsules in several strengths and is taken once a day, with or without food. For GIST and advanced kidney cancer, the usual pattern is a six-week cycle: a dose every day for four weeks, then two weeks off, repeated for as long as the medicine helps and side effects stay manageable. After kidney surgery, treatment follows the same pattern but stops after nine cycles, roughly a year. For pancreatic neuroendocrine tumors, it is taken every day at a lower dose with no planned break. Lowering the dose or pausing treatment is a routine way to manage side effects, and the dose may also change if another medicine that affects sunitinib's levels cannot be avoided. Blood tests are often done before each cycle. If a dose is missed by less than 12 hours, take it right away; if more than 12 hours have passed, skip it and take the next dose at the usual time, and let the care team know. Do not take two doses to make up for one. If too much is taken, call the care team right away.
Most people have some side effects. Tiredness, diarrhea, nausea, poor appetite, indigestion, a changed sense of taste and a sore mouth are common. Hand-foot syndrome, which causes redness, blisters, dryness or painful thickened skin on the palms and soles, is also common and can make walking or using the hands uncomfortable. Blood pressure often rises and may need treatment (a severe headache, dizziness or vision change can signal a sharp rise and is worth a call), and low platelet counts can make nosebleeds and bruising more likely. Because the medicine itself is yellow, it can tint the skin yellowish or lighten the hair. Sunitinib carries a boxed warning, the FDA's most prominent safety warning, because it can cause severe liver damage that has occasionally been fatal. Liver blood tests are checked before starting and during each cycle. Contact the care team right away for yellowing of the eyes, dark urine, itching, or pain under the right ribs. Also contact the care team right away for signs of serious bleeding, such as vomiting or coughing up blood, black or tarry stools or blood in the urine. Fainting, lightheadedness or a fast or irregular heartbeat can reflect a heart rhythm problem and also need a prompt call. For a severe rash with blisters, peeling or painful mouth sores, stop taking sunitinib and contact the care team or get medical help right away. Belly pain that is severe or will not go away needs medical help right away, because sunitinib can rarely cause a tear in the stomach or bowel. Shortness of breath, swollen feet or ankles, or tiredness that keeps worsening can signal a weakened heart and should be reported.
Sunitinib is broken down in the liver by an enzyme called CYP3A4. Medicines that block this enzyme, such as the antifungal ketoconazole, can raise sunitinib levels and the risk of side effects, and grapefruit has a similar effect, so grapefruit and grapefruit juice should be avoided. Medicines that speed the enzyme up, such as rifampin (an antibiotic used for tuberculosis), can lower its levels and make it less effective. Because sunitinib can lengthen the heart's electrical recovery time (the QT interval on an electrocardiogram, or ECG, a recording of the heart's electrical activity), combining it with other medicines that do the same calls for closer heart rhythm checks. Share a full list of prescriptions, over-the-counter medicines and supplements before starting and whenever anything changes. Sunitinib can cause low blood sugar in anyone who takes it, sometimes severe enough to cause fainting or need hospital care. The risk is higher in people taking diabetes medicines, whose doses may need adjusting along with regular blood sugar checks. Contact the care team right away for signs of low blood sugar such as sweating, shakiness, hunger, a fast heartbeat, confusion or unusual drowsiness. Sunitinib slows wound healing and can rarely damage the jawbone (osteonecrosis of the jaw), particularly in people who also take bisphosphonates, bone-strengthening medicines such as those used for osteoporosis. It is usually stopped at least three weeks before planned surgery or invasive dental work, and restarted only when the care team says it is safe. Tell every surgeon and dentist about it, and mention any jaw pain, loose teeth or mouth sores that do not heal. Sunitinib can harm a developing baby. A pregnancy test is done before starting. Women who could become pregnant should use effective birth control during treatment and for at least four weeks after the last dose, and men with partners who could become pregnant should do so for seven weeks after. Breastfeeding is not advised during treatment or for four weeks afterward. Sunitinib may also reduce fertility in both men and women, which is worth raising before starting if future children matter.
Sunitinib is usually continued for as long as it keeps the cancer under control and side effects remain manageable, except after kidney surgery, where treatment ends after nine cycles. Whether it is working is judged mainly with scans, since tumors can shrink or stop growing without any change a person can feel. In the trial that led to its approval for advanced kidney cancer, the cancer was held in check for a median of about 11 months with sunitinib (half of people did better and half did worse than that figure), compared with about 5 months with interferon, the older standard treatment. In pancreatic neuroendocrine tumors, the median was about 10 months compared with about 5 months on placebo, although that trial stopped early, which can make a benefit look larger than it is. Individual results vary widely. Treatment involves regular monitoring: blood pressure (often including home readings), blood counts, liver tests, thyroid tests, since sunitinib can cause thyroid problems that need their own treatment, and urine tests for protein, which can signal kidney strain. Some people also have heart ultrasounds or ECGs, especially with existing heart disease. Dose reductions and short breaks are a normal part of finding a level a person can sustain. Raising problems early, rather than waiting, gives the team the best chance to adjust treatment before a side effect becomes serious.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Sunitinib, what you've noticed, or ask the community a question.